AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00143494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: measurement of abdominal pressure
Description: measurement of abdominal pressure with different volume and saline temperature
Study NCT04874883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Simbyotic
Description: 6 grams of the symbiotic will be administered twice a day
Study NCT04874883 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: 6 grams of the maltodextrin will be administered twice a day
Study NCT01659996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, Intramuscular
Study NCT01659996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed
Description: 0.5 mL, Intramuscular
Study NCT01659996 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
Description: 0.5 mL, Intramuscular
Study NCT02137018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPL fixation by BP
Description: A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
Study NCT02137018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PPL mesh
Description: A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
Study NCT02094378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 84 mg esketamine administered intranasally
Study NCT02094378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine
Description: 84 mg esketamine administered intranasally
Study NCT02094378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intranasally
Study NCT02094378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine load
Description: Dexmedetomidine 1 µg/kg prior to bronchoscopy
Study NCT02157116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02157116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study NCT00744913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm patches
Description: Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
Study NCT00744913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Women in this arm of the study will receive standard counseling only.
Study NCT01862016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APRV
Description: Pressure ventilation mode allowing early spontaneous breathing
Study NCT01862016 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: arterial blood gas measurement each morning
Study NCT01862016 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: arterial blood gas measurement each morning
Study NCT01650896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric assessment review
Description: Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
Study NCT04105816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 892.1550 Ultrasonic pulsed doppler imaging system
Description: Use of the ultrasound to measure quadriceps volume
Study NCT04105816 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 892.1550 Ultrasonic pulsed doppler imaging system
Description: Use of the ultrasound to measure quadriceps volume
Study NCT04105816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thigh circumference measurement
Description: Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
Study NCT04105816 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Thigh circumference measurement
Description: Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
Study NCT00795184 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging procedures (NBI)
Description: Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites.
Study NCT00795184 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HDWLE
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine load
Description: Ketamine 30 mg bolus prior to bronchoscopy
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam load
Description: 2 mg bolus prior to bronchoscopy
Study NCT00901992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEDIAS 2 ICT
Description: MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
Study NCT00901992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current ICT program (ACC-ICT)
Description: This program is conducted in 10 lessons in a group setting (4-8 participants)
Study NCT03887312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: t-CETA
Description: Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.
Study NCT03887312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Médecins du Monde treatment as usual
Description: Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing \[EMDR\] for trauma, Interpersonal Therapy \[IPT\] for depression, Cognitive Behavioural Therapy \[CBT\], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
Study NCT00833001 — intervention group
Intervention type: DEVICE
Intervention: GYNECARE PROLIFT+M* Pelvic Floor Repair System
Description: Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
Study NCT04182282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARES Dementia-Friendly Hospitals Online Training and Certification Program
Description: The CARES Dementia-Friendly Hospitals Online Training program is a 4-course, 16-module, video-based training program for hospital staff members. The CARES Dementia-Friendly Hospitals Online Certification Program is a 100-point certification exam evaluating knowledge from the online training protocol.
Study NCT03279692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
Study NCT00795184 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: pCLE
Study NCT00405275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: baseline methotrexate is maintained throughout the study and is not provided by the sponsor
Study NCT00405275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: sulfasalazine, oral
Study NCT00405275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: hydroxychloroquine, oral
Study NCT00405275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, triple
Description: Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
Study NCT00405275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, etanercept
Description: Participants in triple arm (Arm 2) were given placebo etanercept injections.
Study NCT03726749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
Study NCT03726749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is an anti-inflammatory medication
Study NCT02518568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0355
Description: Oral administration (2 tablets)
Study NCT04297176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin-traditional dosing
Description: The dose is calculated based on 2 vancomycin serum levels
Study NCT03741699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-treatment with rLH (Luveris 75 IU),
Description: Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
Study NCT03671889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Brain Barrier (BBB) Disruption
Description: Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
Study NCT03803787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Description: Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
Study NCT01058772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INDUCTION of LABOUR
Description: Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score \< 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
Study NCT01145508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01145508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT01145508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01145508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01145508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT01145508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT01145508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Description: Given SC
Study NCT01145508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilimogene Galvacirepvec
Description: Given SC
Study NCT04297176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin- Trough-only based dosing
Description: The dose is calculated based on 1 vancomycin serum level (i.e. trough)
Study NCT01711892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Soccer training
Study NCT03638544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reduced gluten bread and Pasta compared o normal gluten bread and Pasta
Description: Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
Study NCT02621749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal replacement therapy
Description: Patients receive renal replacement therapy according to institutional standards
Study NCT04123561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TLC599
Description: TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
Study NCT04123561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599
Description: TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
Study NCT04123561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSP
Description: Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
Study NCT04123561 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% normal saline
Study NCT00394277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 µg sc weekly for 48 weeks
Study NCT00394277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1200 mg po daily for 48 weeks
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl load
Description: 50 µg bolus prior to bronchoscopy
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine maintenance
Description: 0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
Study NCT00446901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Selenium
Description: Selenized yeast, 300 ug/day
Study NCT00446901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Selenized yeast, 300 ug/day
Study NCT00049530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
Study NCT04008849 — intervention group
Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Long term safety and clinical outcomes
Study NCT01371383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Description: EPA 1680 mg/d + DHA 880 mg/d
Study NCT04379557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
Study NCT01371383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Soybean oil
Study NCT03292159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active RAVANS concurrent with arm motor training
Description: Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
Study NCT04379557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
Study NCT04595461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Education
Description: Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine maintenance
Description: 8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam demand
Description: 0.5 mg demand bolus at discretion of pulmonologist
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam demand
Description: 0.5 mg demand bolus at discretion of pulmonologist
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl demand
Description: 12.5 µg demand bolus at discretion of pulmonologist
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl demand
Description: 12.5 µg demand bolus at discretion of pulmonologist
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benadryl demand
Description: 25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
Study NCT01158820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benadryl demand
Description: 25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
Study NCT01849692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESBA1008 solution
Description: Intravitreal injection or infusion
Study NCT01849692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection
Study NCT03914430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
Study NCT02308592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Patient Decision Aid
Description: The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
Study NCT02308592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Resource Sheet
Description: Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization.
Study NCT02308592 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Resource Sheet
Description: Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization.